Medidata Unveils Multi-Sector Research Alliance at the 65th ASH Annual Meeting and Exposition
The Medidata Research Alliance accelerates scientific research via an academic-industry collaborative framework
New York – December 7, 2023 Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of the Medidata Research Alliance. This unique consortium brings together leading clinician-researchers and key opinion leaders from academia, non-profit organizations, and the life sciences industry to leverage Medidata’s expertise in Artificial Intelligence (AI) capabilities and clinical trial data to drive cutting-edge research into innovative treatments.
The Medidata Research Alliance bridges insights from data into clinical practice, fostering scientific exploration that can be applied across multiple therapeutic areas.
"This initiative combines the deep expertise of physician-scientists with Medidata AI and data-driven research to help advance medical breakthroughs - ultimately supporting patients and the broader healthcare and life sciences communities,” said Fareed Melhem, SVP, Medidata AI, Medidata. “Our collective ambition is to drive medical progress by drawing insights from the volume, depth, and richness of our historical clinical trial data.”
One significant area of focus for the Research Alliance is providing a greater understanding of Chimeric antigen receptor T (CAR-T) cell therapy, a promising new therapeutic approach to treat cancer. CAR-T clinical developers face a number of challenges, including life-threatening side effects and a lack of relevant data. Medidata and academic researchers can now partner and leverage the insights from an exclusive CAR-T dataset, generated through the Medidata Data Collaboration Program. And through this effort, collaborators explore clinically impactful hypotheses and jointly conduct research that provides tangible improvements in patient care.
“It’s been a dream come true to partner with such a great group of people at Medidata and to utilize such a robust dataset to explore these hypotheses in a more granular and highly statistically powered way than a single institution may otherwise be able to,” said Theodore Scott Nowicki, MD, PhD, Assistant Professor of Pediatric Hematology/Oncology at the David Geffen School of Medicine, UCLA.
Results from the Research Alliance collaborations will be presented in poster sessions at the 65th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 9-12, 2023:
- Poster 3626: The association of phosphorus disruption and neurotoxicity in patients undergoing CAR-T therapy
- Poster 3629: Significant CRS risk model with T-cell engaging therapies
- Poster 5018: Machine learning-based decision tree for clinical management of neurotoxicity in patients undergoing CAR-T therapy
